Osamu Yamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Osamu Yamamoto has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Budiwan Sumarsono
Astellas Pharma Singapore
1 shared publication - Daisuke Kato
Astellas Pharma Inc. , Tokyo, Japan
1 shared publication - Hidehiro Kakizaki
Asahikawa Medical University
1 shared publication Hiroshi Hiraoka
First Department of Surgery, Yamaguchi University School of Medicine
1 shared publication- Jar Jar Jong
Astellas Pharma Singapore
1 shared publication Kensuke Esato
First Department of Surgery, Yamaguchi University School of Medicine
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 13 (1) , 98-107
Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from theMATCHstudy
Objectives To investigate the cardiovascular safety of mirabegron add-on treatment to tamsulosin in male patients with residual overactive bladder symptoms. Methods This was a post hoc analysis of MATCH, the first double-blind, placebo-controlled study comparing mirabegron and placebo as add-on therapy to tamsulosin for treatment of overactive bladder in men with lower urinary tract symptoms. The analysis focused on treatment-emergent adverse events relating to the cardiovascular system or blood pressure, and changes in vital signs during 12 weeks of follow-up. Results Cardiovascular-related treatment-emergent adverse events were reported by 6/566 patients, although only one serious treatment-emergent adverse event was related to treatment (unstable angina in the tamsulosin + placebo group). Hypertension (two patients) and increased blood pressure (one patient) were reported in the tamsulosin + placebo group, but there were no blood pressure-related treatment-emergent adverse events among tamsulosin + mirabegron patients. There were no clinically meaningful changes from baseline in blood pressure, and changes in pulse rate were small (+1.2 bpm in the tamsulosin + mirabegron group). Increased pulse rate was more frequent with tamsulosin + mirabegron than with tamsulosin + placebo in older patients, although within the normal range. Conclusions Cardiovascular-related adverse events were uncommon in both treatment groups. Mirabegron is a well-tolerated add-on therapy to tamsulosin in Japanese and Korean males with residual overactive bladder symptoms.
- 1 January 2021
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 13 (1) , 98-107
Open AccessCardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from theMATCHstudy
Objectives To investigate the cardiovascular safety of mirabegron add-on treatment to tamsulosin in male patients with residual overactive bladder symptoms. Methods This was a post hoc analysis of MATCH, the first double-blind, placebo-controlled study comparing mirabegron and placebo as add-on therapy to tamsulosin for treatment of overactive bladder in men with lower urinary tract symptoms. The analysis focused on treatment-emergent adverse events relating to the cardiovascular system or blood pressure, and changes in vital signs during 12 weeks of follow-up. Results Cardiovascular-related treatment-emergent adverse events were reported by 6/566 patients, although only one serious treatment-emergent adverse event was related to treatment (unstable angina in the tamsulosin + placebo group). Hypertension (two patients) and increased blood pressure (one patient) were reported in the tamsulosin + placebo group, but there were no blood pressure-related treatment-emergent adverse events among tamsulosin + mirabegron patients. There were no clinically meaningful changes from baseline in blood pressure, and changes in pulse rate were small (+1.2 bpm in the tamsulosin + mirabegron group). Increased pulse rate was more frequent with tamsulosin + mirabegron than with tamsulosin + placebo in older patients, although within the normal range. Conclusions Cardiovascular-related adverse events were uncommon in both treatment groups. Mirabegron is a well-tolerated add-on therapy to tamsulosin in Japanese and Korean males with residual overactive bladder symptoms.
- Open Access
- 1 January 1993
- Published by Japan Surgical Association in The journal of the Japanese Practical Surgeon Society
- Vol. 54 (10) , 2687-2689
A SURGICAL CASE OF SUPERIOR LUMBAR HERNIA
The resistance-declined portion in the lumbar region is well known as the lumbar triangle anatomically, and it is extremely rate that hernia occurs in the same region. We experienced a case of superior lumbar hernia presented with a left frank mass. A 70-year-old man was seen at the clinic because of left frank mass which was noticed about one year before. CT revealed a tumor protruded from the defect of the aponeurosis in the lumbar dorsal region. It was inferred that hernia content was the fat around the kidney. With the diagnosis of superior lumbar hernia, herniorrhaphy was performed. Hernia defect, 3cm diamiter and bounded superiorly by the 12th rib, medially by the quadrates lumborum muscle, and laterally by the external oblique, was closed with interrupted nonabsorbable sutures without tension. The postoperative course was uneventful. There has been no recurrence, as of 5 months after the operation.
- 1 January 1993
- Published by Japan Surgical Association in The journal of the Japanese Practical Surgeon Society
- Vol. 54 (10) , 2687-2689
Open AccessA SURGICAL CASE OF SUPERIOR LUMBAR HERNIA
The resistance-declined portion in the lumbar region is well known as the lumbar triangle anatomically, and it is extremely rate that hernia occurs in the same region. We experienced a case of superior lumbar hernia presented with a left frank mass. A 70-year-old man was seen at the clinic because of left frank mass which was noticed about one year before. CT revealed a tumor protruded from the defect of the aponeurosis in the lumbar dorsal region. It was inferred that hernia content was the fat around the kidney. With the diagnosis of superior lumbar hernia, herniorrhaphy was performed. Hernia defect, 3cm diamiter and bounded superiorly by the 12th rib, medially by the quadrates lumborum muscle, and laterally by the external oblique, was closed with interrupted nonabsorbable sutures without tension. The postoperative course was uneventful. There has been no recurrence, as of 5 months after the operation.